According to the company, vaccination with the Moderna COVID-19 vaccine (mRNA-1273) produced neutralising titers against all key emerging variants tested, including B.1.1.7 and B.1.351, first identified in the
The study showed no significant impact on neutralising titers against the B.1.1.7 variant relative to prior variants. A six-fold reduction in neutralising titers was observed with the B.1.351 variant relative to prior variants. Despite this reduction, neutralising titer levels with B.1.351 remain above levels that are expected to be protective.
Therefore the two-dose regimen of mRNA-1273 at the 100µg dose is expected to be protective against all emerging strains detected to date.
"As we seek to defeat the COVID-19 virus, which has created a worldwide pandemic, we believe it is imperative to be proactive as the virus evolves. We are encouraged by these new data, which reinforce our confidence that the Moderna COVID-19 vaccine should be protective against these newly detected variants," said
The data has been submitted as a pre-print to bioRxiv and will be submitted for peer-reviewed publication.
Pfizer COVID-19 vaccine effective against B.1.1.7 variant from UK…
The post Moderna COVID-19 vaccine successful against emerging variants, study shows appeared first on European Pharmaceutical Review.
© Russell Publishing Limited, 2021. All Rights Reserved., source